- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Clinical Trials
- April 2024
- 390 Pages
Global
From €2370EUR$2,500USD£1,980GBP
- Report
- October 2024
- 450 Pages
Global
From €3787EUR$3,995USD£3,163GBP
- Report
- November 2023
- 148 Pages
Global
From €4218EUR$4,450USD£3,524GBP
- Report
- February 2024
- 180 Pages
Global
From €4710EUR$4,969USD£3,935GBP
- Report
- January 2024
- 297 Pages
Global
€4734EUR$4,995USD£3,955GBP
- Report
- February 2024
- 380 Pages
Global
€4734EUR$4,995USD£3,955GBP
- Report
- October 2024
- 106 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Book
- December 2024
- 1440 Pages
- Book
- March 2021
- 208 Pages
- Book
- January 2020
- 504 Pages
- Book
- January 2020
- 504 Pages
- Book
- December 2019
- 2656 Pages
- Book
- December 2019
- 2656 Pages
- Book
- April 2018
- 224 Pages

Scleroderma is a chronic skin condition that affects the connective tissue of the skin and other organs. It is characterized by hardening and thickening of the skin, as well as joint pain and stiffness. It can also cause damage to the lungs, heart, and kidneys. Treatment for scleroderma includes medications, physical therapy, and lifestyle changes.
The scleroderma market within the context of dermatology is a growing one, with a focus on developing treatments that can improve the quality of life for those affected. There is a need for more effective treatments, as well as better diagnosis and management of the condition.
Some companies in the scleroderma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more